10-Q 1 zbh-20240930.htm 10-Q 10-Q
falseQ3--12-31false0001136869http://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#AssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#AssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://www.zimmerbiomet.com/20240930#AcquisitionIntegrationDivestitureAndRelatedExpenseshttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#InterestIncomeExpenseNethttp://fasb.org/us-gaap/2024#InterestIncomeExpenseNethttp://fasb.org/us-gaap/2024#InterestIncomeExpenseNethttp://fasb.org/us-gaap/2024#InterestIncomeExpenseNethttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#InterestIncomeExpenseNethttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#InterestIncomeExpenseNethttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#InterestIncomeExpenseNethttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#InterestIncomeExpenseNethttp://fasb.org/us-gaap/2024#AssetsCurrenthttp://fasb.org/us-gaap/2024#AssetsCurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AssetsCurrenthttp://fasb.org/us-gaap/2024#AssetsCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent0001136869us-gaap:TrademarksAndTradeNamesMemberzbh:DistributorAndVideoInterventionnelleMedicaleScientifiqueAcquisitionMember2024-09-300001136869us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-09-300001136869us-gaap:CashFlowHedgingMemberzbh:ForwardStartingInterestRateSwapsMember2024-07-012024-09-300001136869us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-09-300001136869us-gaap:OperatingSegmentsMemberus-gaap:EMEAMember2024-07-012024-09-300001136869us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001136869us-gaap:SeniorNotesMemberzbh:TwoThousandThirtyNineMemberzbh:FivePointSevenFiveZeroPercentageMember2023-12-310001136869zbh:EmployeeTerminationBenefitsMemberzbh:TwoThousandTwentyOneRestructuringPlanMember2024-01-012024-09-300001136869zbh:TwoThousandTwentyThreeRestructuringPlanMember2024-07-012024-09-300001136869us-gaap:OtherRestructuringMemberzbh:TwoThousandTwentyOneRestructuringPlanMember2024-07-012024-09-300001136869us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-07-012024-09-300001136869zbh:TwoThousandTwentySevenMemberzbh:OnePointOneSixFourPercentageMemberzbh:EuroNotesMember2023-12-310001136869us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMember2024-01-012024-09-300001136869us-gaap:NoncontrollingInterestMember2024-06-300001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherAssetsMemberus-gaap:CrossCurrencyInterestRateContractMember2023-12-310001136869us-gaap:SeniorNotesMemberzbh:TwoThousandThirtyMemberzbh:ThreePointFiveFiveZeroPercentageMember2023-12-310001136869zbh:HipsMember2023-01-012023-09-300001136869us-gaap:TreasuryStockCommonMember2023-12-310001136869us-gaap:CashFlowHedgingMember2023-12-310001136869zbh:OctoberTwoThousandTwentyThreeAcquisitionMember2023-10-060001136869srt:AmericasMember2023-01-012023-09-300001136869us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001136869zbh:TwoThousandTwentyFourFiveYearCreditAgreementMember2024-09-300001136869us-gaap:CommonStockMember2024-07-012024-09-300001136869us-gaap:CashFlowHedgingMember2024-07-012024-09-300001136869zbh:OthersCountriesMember2023-07-012023-09-300001136869us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherNonoperatingIncomeExpenseMember2024-01-012024-09-300001136869us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2023-12-310001136869zbh:TwoThousandNineteenRestructuringPlanMemberus-gaap:ContractTerminationMember2024-09-300001136869zbh:CorporateItemsMember2023-07-012023-09-300001136869zbh:KneesMember2023-07-012023-09-3000011368692023-12-310001136869zbh:SETMember2024-07-012024-09-300001136869zbh:TwoThousandTwentyOneRestructuringPlanMember2024-07-012024-09-300001136869zbh:TwoThousandTwentyThreeRestructuringPlanMemberus-gaap:OtherRestructuringMember2024-07-012024-09-300001136869us-gaap:OtherRestructuringMemberzbh:TwoThousandTwentyOneRestructuringPlanMember2023-12-310001136869country:US2024-01-012024-09-300001136869us-gaap:NondesignatedMember2024-09-300001136869zbh:TwoThousandNineteenRestructuringPlanMember2024-09-300001136869us-gaap:CrossCurrencyInterestRateContractMember2024-01-012024-09-300001136869us-gaap:SeniorNotesMemberzbh:FivePointTwoZeroPercentageMemberzbh:TwoThousandThirtyFourMember2023-12-310001136869zbh:OctoberTwoThousandTwentyThreeAcquisitionMembersrt:MaximumMember2023-10-060001136869us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001136869us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001136869zbh:EuroNotesMember2024-07-012024-09-300001136869us-gaap:ConstructionInProgressMember2024-09-300001136869us-gaap:CommonStockMember2024-01-012024-09-300001136869us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeForwardMember2024-07-012024-09-300001136869us-gaap:TrademarksAndTradeNamesMember2023-01-012023-12-310001136869us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-07-012023-09-300001136869zbh:EuroNotesMember2023-07-012023-09-300001136869us-gaap:NoncontrollingInterestMember2024-01-012024-09-300001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001136869us-gaap:OperatingSegmentsMemberus-gaap:EMEAMember2024-01-012024-09-300001136869us-gaap:ContractTerminationMemberzbh:TwoThousandTwentyOneRestructuringPlanMember2024-09-300001136869zbh:CorporateItemsMember2024-01-012024-09-300001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeForwardMember2024-09-3000011368692023-07-012023-09-300001136869zbh:ShortTermTermLoanMemberus-gaap:CashMember2023-01-012023-09-300001136869zbh:CashFlowHedgesOneMember2024-09-300001136869zbh:TwoThousandTwentyThreeRestructuringPlanMemberus-gaap:ContractTerminationMember2024-01-012024-09-300001136869us-gaap:TreasuryStockCommonMember2023-01-012023-09-300001136869us-gaap:AdditionalPaidInCapitalMember2024-09-300001136869us-gaap:NondesignatedMember2023-12-310001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherLiabilitiesMember2024-09-300001136869us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-09-300001136869zbh:TwoThousandTwentyThreeRestructuringPlanMemberzbh:EmployeeTerminationBenefitsMember2024-01-012024-09-300001136869us-gaap:ContractTerminationMemberzbh:TwoThousandTwentyOneRestructuringPlanMember2024-07-012024-09-300001136869us-gaap:RetainedEarningsMember2022-12-310001136869us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-07-012023-09-300001136869us-gaap:DevelopedTechnologyRightsMemberzbh:DistributorAndVideoInterventionnelleMedicaleScientifiqueAcquisitionMember2024-09-300001136869zbh:OnePointOneSixFourPercentageNotesDueTwoThousandTwentySevenMember2024-01-012024-09-300001136869zbh:TwoThousandTwentyThreeFiveYearCreditAgreementMember2023-07-070001136869zbh:DistributorAcquisitionMember2024-04-022024-04-020001136869us-gaap:SeniorNotesMemberzbh:TwoThousandThirtyOneMemberzbh:TwoPointSixZeroPercentageMember2024-09-3000011368692024-01-012024-09-300001136869us-gaap:AdditionalPaidInCapitalMember2024-06-300001136869zbh:HipsMember2024-07-012024-09-300001136869zbh:MultiCurrencyRevolvingFacilityMemberzbh:TwoThousandTwentyThreeFiveYearCreditAgreementMember2023-07-070001136869us-gaap:CrossCurrencyInterestRateContractMember2024-07-012024-09-3000011368692024-08-152024-08-150001136869us-gaap:TreasuryStockCommonMember2022-12-310001136869us-gaap:CashFlowHedgingMember2024-01-012024-09-300001136869us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeForwardMember2023-07-012023-09-300001136869zbh:TwoThousandNineteenRestructuringPlanMemberus-gaap:OtherRestructuringMember2024-07-012024-09-3000011368692023-01-012023-09-300001136869us-gaap:NoncontrollingInterestMember2023-09-300001136869us-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMemberus-gaap:CrossCurrencyInterestRateContractMember2024-01-012024-09-300001136869us-gaap:OperatingSegmentsMemberus-gaap:EMEAMember2023-07-012023-09-300001136869us-gaap:SeniorNotesMemberzbh:TwoThousandTwentyFiveMemberzbh:ThreePointFiveFiveZeroPercentageMember2023-12-310001136869srt:AmericasMember2024-07-012024-09-300001136869us-gaap:SeniorNotesMemberzbh:TwoThousandFortyFiveMemberzbh:FourPointFourFiveZeroPercentageMember2024-01-012024-09-300001136869zbh:SETMember2023-01-012023-09-300001136869us-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMemberus-gaap:CrossCurrencyInterestRateContractMember2023-01-012023-09-300001136869zbh:BuildingsAndEquipmentMember2023-12-310001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001136869us-gaap:SeniorNotesMemberzbh:TwoThousandTwentyFiveMemberzbh:ThreePointFiveFiveZeroPercentageMember2024-09-300001136869us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2024-07-012024-09-300001136869us-gaap:CommonStockMember2023-01-012023-09-300001136869zbh:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditAndUnrecognizedActuarialGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-09-300001136869zbh:VideoInterventionnelleMedicaleScientifiqueMember2024-04-292024-04-290001136869zbh:EmployeeTerminationBenefitsMemberzbh:TwoThousandTwentyOneRestructuringPlanMember2024-07-012024-09-300001136869zbh:TwoThousandTwentyThreeRestructuringPlanMemberus-gaap:OtherRestructuringMember2023-12-310001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeForwardMember2023-12-310001136869us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001136869us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-09-300001136869zbh:TwoThousandTwentyFourThreeSixtyFourDayRevolvingCreditAgreementMember2024-09-300001136869zbh:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditAndUnrecognizedActuarialGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-07-012024-09-300001136869zbh:TwoThousandNineteenRestructuringPlanMemberzbh:EmployeeTerminationBenefitsMember2023-12-310001136869us-gaap:CashFlowHedgingMemberzbh:ForwardStartingInterestRateSwapsMember2023-01-012023-09-300001136869zbh:CarryingAmountOfHedgedLiabilitiesMember2024-09-300001136869zbh:CashFlowHedgesOneMember2023-12-310001136869us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001136869zbh:TaxYears2016To2019Member2024-09-300001136869us-gaap:RetainedEarningsMember2024-01-012024-09-3000011368692024-06-300001136869us-gaap:FairValueInputsLevel2Memberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeForwardMember2023-12-310001136869us-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeForwardMember2023-12-310001136869us-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2023-12-310001136869us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherAssetsMemberus-gaap:ForeignExchangeForwardMember2024-09-300001136869zbh:EmbodyIncMember2023-02-140001136869us-gaap:RetainedEarningsMember2024-06-300001136869zbh:CrossCurrencyInterestRateContractMaturedMember2024-01-012024-09-300001136869us-gaap:CommonStockMember2022-12-310001136869us-gaap:CashFlowHedgingMember2024-09-300001136869us-gaap:AdditionalPaidInCapitalMember2023-09-300001136869zbh:InstrumentsMember2024-09-300001136869zbh:TwoThousandTwentySevenMemberzbh:OnePointOneSixFourPercentageMemberzbh:EuroNotesMember2024-09-300001136869zbh:TwoThousandTwentyOneRestructuringPlanMember2021-12-310001136869us-gaap:OtherRestructuringMemberzbh:TwoThousandTwentyOneRestructuringPlanMember2024-09-300001136869country:US2023-07-012023-09-300001136869zbh:EuroNotesMember2023-01-012023-09-300001136869us-gaap:InterestExpenseMember2023-01-012023-09-300001136869zbh:MultiCurrencyRevolvingFacilityMemberzbh:TwoThousandTwentyThreeFiveYearCreditAgreementMember2023-07-072023-07-070001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001136869us-gaap:RetainedEarningsMember2023-06-3000011368692024-10-250001136869zbh:TwoThousandTwentyOneRestructuringPlanMember2024-09-300001136869us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001136869us-gaap:CostOfSalesMember2024-09-300001136869zbh:TwoThousandTwentyThreeAcquisitionsMemberus-gaap:DevelopedTechnologyRightsMember2023-12-3100011368692024-08-150001136869us-gaap:AdditionalPaidInCapitalMember2023-06-300001136869us-gaap:CostOfSalesMember2023-01-012023-09-300001136869us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-09-300001136869us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001136869zbh:DistributorAndVideoInterventionnelleMedicaleScientifiqueAcquisitionMember2024-09-300001136869us-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMemberus-gaap:CrossCurrencyInterestRateContractMember2024-07-012024-09-300001136869zbh:TwoThousandTwentyThreeRestructuringPlanMemberzbh:EmployeeTerminationBenefitsMember2023-12-310001136869zbh:TwoThousandTwentyThreeRestructuringPlanMemberus-gaap:ContractTerminationMember2024-07-012024-09-300001136869zbh:TwoThousandTwentyThreeAcquisitionsMemberus-gaap:TrademarksAndTradeNamesMember2023-12-310001136869us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2024-01-012024-09-300001136869us-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001136869zbh:CMFTAcquisitionMember2024-08-162024-08-160001136869zbh:TwoThousandTwentyOneRestructuringPlanMember2023-12-310001136869us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-09-3000011368692024-07-012024-09-300001136869us-gaap:CommonStockMember2023-07-012023-09-300001136869us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001136869us-gaap:CommonStockMemberzbh:EmbodyIncMember2024-09-3000011368692023-01-012023-12-310001136869zbh:TwoThousandTwentyFourThreeSixtyFourDayRevolvingCreditAgreementMembersrt:MaximumMember2024-09-300001136869us-gaap:SeniorNotesMemberzbh:TwoThousandThirtyMemberzbh:ThreePointFiveFiveZeroPercentageMember2024-09-300001136869zbh:AprilTwoThousandTwentyThreeAcquisitionMembersrt:MaximumMember2023-04-280001136869us-gaap:ContractTerminationMemberzbh:TwoThousandTwentyOneRestructuringPlanMember2024-01-012024-09-300001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMember2024-09-300001136869us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-07-012023-09-300001136869us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001136869us-gaap:TreasuryStockCommonMember2024-06-300001136869zbh:OthersCountriesMember2024-01-012024-09-300001136869zbh:TwoThousandTwentyFourFiveYearCreditAgreementMemberzbh:MultiCurrencyRevolvingFacilityMember2024-06-2800011368692022-12-310001136869us-gaap:OtherRestructuringMemberzbh:TwoThousandTwentyOneRestructuringPlanMember2024-01-012024-09-300001136869us-gaap:InterestExpenseMember2024-09-300001136869us-gaap:FairValueMeasurementsRecurringMember2024-09-300001136869zbh:TwoThousandTwentyFourFiveYearCreditAgreementMembersrt:MaximumMember2024-09-300001136869us-gaap:SeniorNotesMemberzbh:FivePointTwoZeroPercentageMemberzbh:TwoThousandThirtyFourMember2024-08-150001136869us-gaap:SeniorNotesMemberzbh:FivePointThreeFiveZeroPercentageMemberzbh:TwoThousandTwentyEightMember2024-09-300001136869us-gaap:DevelopedTechnologyRightsMember2023-01-012023-12-310001136869us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-01-012024-09-300001136869us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-09-300001136869us-gaap:SeniorNotesMemberzbh:TwoThousandTwentyThreeMemberzbh:ThreePointSevenZeroPercentageSeniorNotesDue2023Member2023-09-300001136869country:US2023-01-012023-09-300001136869zbh:TwoThousandTwentyThreeRestructuringPlanMemberzbh:EmployeeTerminationBenefitsMember2024-07-012024-09-300001136869us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberzbh:ForwardStartingInterestRateSwapsMember2024-01-012024-09-300001136869us-gaap:CostOfSalesMember2024-01-012024-09-300001136869us-gaap:CommonStockMemberzbh:EmbodyIncMember2023-02-140001136869us-gaap:ContractTerminationMemberzbh:TwoThousandTwentyOneRestructuringPlanMember2023-12-310001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMember2023-12-310001136869us-gaap:CashFlowHedgingMemberzbh:ForwardStartingInterestRateSwapsMember2023-07-012023-09-300001136869us-gaap:CommonStockMemberzbh:EmbodyIncMember2023-02-142023-02-140001136869us-gaap:TreasuryStockCommonMember2024-01-012024-09-300001136869us-gaap:TreasuryStockCommonMember2024-09-300001136869zbh:DistributorAndVideoInterventionnelleMedicaleScientifiqueAcquisitionMemberus-gaap:CustomerRelationshipsMember2024-09-300001136869zbh:CrossCurrencyInterestRateContractMaturedMember2024-09-300001136869us-gaap:CashFlowHedgingMember2023-07-012023-09-300001136869us-gaap:InterestExpenseMember2024-07-012024-09-300001136869us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-09-300001136869us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001136869zbh:TwoThousandNineteenRestructuringPlanMember2023-12-310001136869us-gaap:RetainedEarningsMember2023-09-300001136869zbh:TwoThousandNineteenRestructuringPlanMemberus-gaap:OtherRestructuringMember2024-09-300001136869us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeForwardMember2024-01-012024-09-300001136869us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-12-310001136869us-gaap:AdditionalPaidInCapitalMember2023-12-310001136869us-gaap:OperatingSegmentsMembersrt:AsiaPacificMember2023-01-012023-09-300001136869srt:AmericasMember2023-07-012023-09-300001136869zbh:TwoThousandTwentyThreeAcquisitionsMember2024-01-012024-09-300001136869us-gaap:FairValueMeasurementsRecurringMember2023-12-310001136869zbh:OtherProductCategoryMember2023-07-012023-09-300001136869us-gaap:NoncontrollingInterestMember2024-09-300001136869us-gaap:CrossCurrencyInterestRateContractMember2023-01-012023-09-300001136869currency:CHFus-gaap:ForeignExchangeContractMember2024-09-300001136869zbh:TwoThousandNineteenRestructuringPlanMemberus-gaap:ContractTerminationMember2023-12-310001136869us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001136869zbh:OtherProductCategoryMember2024-01-012024-09-300001136869zbh:TwoThousandNineteenRestructuringPlanMemberzbh:EmployeeTerminationBenefitsMember2024-09-300001136869zbh:EmployeeTerminationBenefitsMemberzbh:TwoThousandTwentyOneRestructuringPlanMember2024-09-300001136869zbh:TaxYears2013To2015Member2024-09-300001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001136869us-gaap:OperatingSegmentsMemberus-gaap:EMEAMember2023-01-012023-09-300001136869zbh:UncommittedCreditFacilityMember2023-08-280001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001136869zbh:KneesMember2023-01-012023-09-300001136869us-gaap:CommonStockMember2024-09-300001136869us-gaap:TrademarksAndTradeNamesMember2024-01-012024-09-300001136869zbh:NovemberTwoThousandTwentyThreeAcquisitionMembersrt:MaximumMember2023-11-150001136869us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMembersrt:MaximumMember2024-09-300001136869us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001136869us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310001136869srt:AmericasMember2024-01-012024-09-300001136869us-gaap:NoncontrollingInterestMember2023-07-012023-09-300001136869us-gaap:NondesignatedMemberus-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMember2023-12-310001136869zbh:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditAndUnrecognizedActuarialGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-07-012023-09-300001136869us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001136869zbh:HipsMember2024-01-012024-09-300001136869us-gaap:CostOfSalesMember2024-07-012024-09-300001136869zbh:TwoThousandTwentyThreeRestructuringPlanMember2024-09-300001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:CrossCurrencyInterestRateContractMember2024-09-300001136869zbh:HipsMember2023-07-012023-09-300001136869zbh:TwoThousandTwentyThreeRestructuringPlanMember2024-01-012024-09-300001136869zbh:TwoThousandTwentySixMemberzbh:TwoPointFourTwoFivePercentageMemberzbh:EuroNotesMember2024-09-300001136869zbh:CorporateItemsMember2024-07-012024-09-300001136869zbh:TwoThousandTwentyOneRestructuringPlanMember2024-01-012024-09-300001136869zbh:TwoThousandTwentyThreeRestructuringPlanMemberus-gaap:OtherRestructuringMember2024-01-012024-09-300001136869us-gaap:IntellectualPropertyMember2023-09-300001136869zbh:TwoThousandNineteenRestructuringPlanMember2024-01-012024-09-300001136869zbh:OthersCountriesMember2024-07-012024-09-300001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:CrossCurrencyInterestRateContractMember2023-12-310001136869zbh:TwoThousandTwentyThreeRestructuringPlanMemberzbh:EmployeeTerminationBenefitsMember2024-09-300001136869us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001136869srt:MinimumMemberzbh:TwoThousandTwentyFourFiveYearCreditAgreementMember2024-09-300001136869zbh:BuildingsAndEquipmentMember2024-09-300001136869zbh:TwoThousandTwentyThreeThreeSixtyFourDayRevolvingCreditAgreementMember2024-06-280001136869us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2023-07-012023-09-300001136869zbh:TwoThousandNineteenRestructuringPlanMember2024-07-012024-09-300001136869zbh:SETMember2023-07-012023-09-300001136869zbh:OtherProductCategoryMember2024-07-012024-09-300001136869zbh:UncommittedCreditFacilityMember2024-09-300001136869zbh:DistributorAndVideoInterventionnelleMedicaleScientifiqueAcquisitionMembersrt:MaximumMember2024-09-300001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherLiabilitiesMember2023-12-310001136869us-gaap:OperatingSegmentsMembersrt:AsiaPacificMember2023-07-012023-09-300001136869us-gaap:SeniorNotesMemberzbh:TwoThousandThirtyFiveMemberzbh:FourPointTwoFiveZeroPercentageMember2024-09-300001136869us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-09-300001136869us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherNonoperatingIncomeExpenseMember2023-01-012023-09-300001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:OtherLiabilitiesMember2024-09-300001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherAssetsMemberus-gaap:CrossCurrencyInterestRateContractMember2024-09-300001136869us-gaap:SeniorNotesMemberzbh:TwoThousandFortyFiveMemberzbh:FourPointFourFiveZeroPercentageMember2024-09-300001136869us-gaap:NoncontrollingInterestMember2023-01-012023-09-300001136869us-gaap:SeniorNotesMemberzbh:FivePointTwoZeroPercentageMemberzbh:TwoThousandThirtyFourMember2024-09-300001136869us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300001136869zbh:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditAndUnrecognizedActuarialGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-09-300001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:OtherLiabilitiesMember2023-12-310001136869us-gaap:CashFlowHedgingMemberzbh:ForwardStartingInterestRateSwapsMember2024-01-012024-09-300001136869us-gaap:CustomerRelationshipsMember2023-01-012023-12-310001136869zbh:TwoThousandTwentyThreeRestructuringPlanMember2023-12-310001136869us-gaap:SeniorNotesMemberzbh:FivePointThreeFiveZeroPercentageMemberzbh:TwoThousandTwentyEightMember2023-12-310001136869zbh:CumulativeFairValueHedgingAdjustmentCarryingAmountOfHedgedLiabilitiesMemberzbh:LongTermDebtNoncurrentMember2023-12-310001136869zbh:ShortTermTermLoanMember2023-01-012023-09-300001136869us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001136869zbh:TwoThousandNineteenRestructuringPlanMemberzbh:EmployeeTerminationBenefitsMember2024-07-012024-09-300001136869us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001136869zbh:TwoThousandTwentyThreeAcquisitionsMemberus-gaap:CustomerRelationshipsMember2023-12-310001136869us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMember2024-07-012024-09-300001136869us-gaap:OperatingSegmentsMembersrt:AsiaPacificMember2024-01-012024-09-300001136869zbh:OrthogridSystemsIncMemberus-gaap:SubsequentEventMember2024-10-010001136869us-gaap:SeniorNotesMemberzbh:TwoThousandTwentyFourMemberzbh:OnePointFourFiveZeroPercentageMember2023-12-310001136869us-gaap:RetainedEarningsMember2023-01-012023-09-300001136869us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001136869us-gaap:RetainedEarningsMember2023-12-310001136869us-gaap:SeniorNotesMemberzbh:TwoThousandTwentySixMemberzbh:ThreePointZeroFiveZeroPercentageMember2024-09-300001136869us-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMemberus-gaap:CrossCurrencyInterestRateContractMember2023-07-012023-09-300001136869zbh:OtherProductCategoryMember2023-01-012023-09-300001136869us-gaap:SeniorNotesMemberzbh:TwoThousandFortyFiveMemberzbh:FourPointFourFiveZeroPercentageMember2023-12-310001136869zbh:CrossCurrencyInterestRateContractMaturedMember2023-09-300001136869us-gaap:SeniorNotesMemberzbh:TwoThousandThirtyFiveMemberzbh:FourPointTwoFiveZeroPercentageMember2023-12-310001136869zbh:KneesMember2024-07-012024-09-300001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherLiabilitiesMember2024-09-300001136869zbh:CumulativeFairValueHedgingAdjustmentCarryingAmountOfHedgedLiabilitiesMemberzbh:LongTermDebtNoncurrentMember2024-09-300001136869us-gaap:SeniorNotesMemberzbh:TwoThousandTwentyThreeMemberzbh:ThreePointSevenZeroPercentageSeniorNotesDue2023Member2023-01-012023-09-300001136869us-gaap:NoncontrollingInterestMember2022-12-310001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMember2024-09-300001136869us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2024-07-012024-09-300001136869us-gaap:TreasuryStockCommonMember2023-06-300001136869us-gaap:CommonStockMember2024-01-012024-09-300001136869us-gaap:SeniorNotesMemberzbh:TwoThousandThirtyNineMemberzbh:FivePointSevenFiveZeroPercentageMember2024-09-300001136869us-gaap:RetainedEarningsMember2024-07-012024-09-300001136869us-gaap:OperatingSegmentsMembersrt:AsiaPacificMember2024-07-012024-09-300001136869us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2024-01-012024-09-300001136869us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMember2023-07-012023-09-300001136869zbh:UncommittedCreditFacilityMember2023-12-310001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeForwardMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001136869us-gaap:CommonStockMember2023-09-300001136869us-gaap:InterestExpenseMember2024-01-012024-09-300001136869us-gaap:CommonStockMember2023-06-300001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeForwardMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001136869us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberzbh:ForwardStartingInterestRateSwapsMember2024-07-012024-09-300001136869us-gaap:CrossCurrencyInterestRateContractMember2023-07-012023-09-300001136869us-gaap:RetainedEarningsMember2023-07-012023-09-300001136869us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001136869us-gaap:CommonStockMemberzbh:EmbodyIncMember2024-01-012024-09-300001136869us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001136869zbh:KneesMember2024-01-012024-09-300001136869us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-09-300001136869us-gaap:TreasuryStockCommonMember2024-07-012024-09-300001136869zbh:TwoThousandNineteenRestructuringPlanMemberzbh:EmployeeTerminationBenefitsMember2024-01-012024-09-300001136869us-gaap:CommonStockMember2023-12-310001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherLiabilitiesMember2023-12-310001136869zbh:TwoThousandTwentyThreeRestructuringPlanMemberus-gaap:OtherRestructuringMember2024-09-300001136869us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001136869us-gaap:InProcessResearchAndDevelopmentMemberzbh:TwoThousandTwentyThreeAcquisitionsMember2023-12-310001136869zbh:TwoThousandTwentyFourThreeSixtyFourDayRevolvingCreditAgreementMember2024-06-280001136869us-gaap:DevelopedTechnologyRightsMember2024-01-012024-09-300001136869us-gaap:InProcessResearchAndDevelopmentMemberzbh:EmbodyIncMember2023-09-300001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMember2023-12-310001136869zbh:NovemberTwoThousandTwentyThreeAcquisitionMember2023-11-152023-11-1500011368692023-06-3000011368692023-09-300001136869us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherNonoperatingIncomeExpenseMember2024-07-012024-09-300001136869zbh:EmployeeTerminationBenefitsMemberzbh:TwoThousandTwentyOneRestructuringPlanMember2023-12-310001136869us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001136869us-gaap:SeniorNotesMemberzbh:TwoThousandThirtyOneMemberzbh:TwoPointSixZeroPercentageMember2023-12-310001136869us-gaap:RetainedEarningsMember2024-09-300001136869zbh:InstrumentsMember2023-12-310001136869zbh:DistributorAndVideoInterventionnelleMedicaleScientifiqueAcquisitionMember2024-01-012024-09-300001136869zbh:AprilTwoThousandTwentyThreeAcquisitionMember2023-04-282023-04-280001136869zbh:OtherContingenciesMember2024-09-300001136869zbh:TwoThousandNineteenRestructuringPlanMemberus-gaap:ContractTerminationMember2024-01-012024-09-300001136869us-gaap:SeniorNotesMemberzbh:TwoThousandTwentyFourMemberzbh:OnePointFourFiveZeroPercentageMember2024-09-300001136869zbh:CrossCurrencyInterestRateContractMaturedMember2023-01-012023-09-300001136869us-gaap:CommonStockMember2024-06-300001136869zbh:OctoberTwoThousandTwentyThreeAcquisitionMember2023-10-062023-10-060001136869us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherNonoperatingIncomeExpenseMember2023-07-012023-09-300001136869us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-01-012023-09-300001136869us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001136869zbh:OthersCountriesMember2023-01-012023-09-300001136869us-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001136869srt:MinimumMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2024-09-300001136869us-gaap:SeniorNotesMemberzbh:TwoThousandTwentySixMemberzbh:ThreePointZeroFiveZeroPercentageMember2023-12-310001136869us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherAssetsMemberus-gaap:ForeignExchangeForwardMember2023-12-310001136869us-gaap:CashFlowHedgingMember2023-01-012023-09-3000011368692024-09-300001136869zbh:TwoThousandTwentyThreeAcquisitionsMember2023-12-310001136869zbh:TwoThousandTwentyThreeRestructuringPlanMemberus-gaap:ContractTerminationMember2024-09-300001136869zbh:TwoThousandNineteenRestructuringPlanMember2019-12-310001136869us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2024-09-300001136869us-gaap:LandMember2024-09-300001136869zbh:TwoThousandTwentyFourThreeSixtyFourDayRevolvingCreditAgreementMember2024-06-282024-06-280001136869us-gaap:AdditionalPaidInCapitalMember2022-12-310001136869us-gaap:LandMember2023-12-310001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001136869us-gaap:CrossCurrencyInterestRateContractMember2024-09-300001136869zbh:TwoThousandNineteenRestructuringPlanMemberus-gaap:OtherRestructuringMember2023-12-310001136869currency:USDus-gaap:ForeignExchangeContractMember2024-09-300001136869zbh:EmbodyIncMember2023-02-142023-02-140001136869zbh:CarryingAmountOfHedgedLiabilitiesMember2023-12-310001136869zbh:CorporateItemsMember2023-01-012023-09-300001136869us-gaap:InterestExpenseMember2023-07-012023-09-300001136869country:US2024-07-012024-09-300001136869us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001136869zbh:SETMember2024-01-012024-09-300001136869zbh:TwoThousandTwentyFourThreeSixtyFourDayRevolvingCreditAgreementMembersrt:MinimumMember2024-09-300001136869us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310001136869us-gaap:NoncontrollingInterestMember2024-07-012024-09-300001136869zbh:TwoThousandTwentySixMemberzbh:TwoPointFourTwoFivePercentageMemberzbh:EuroNotesMember2023-12-310001136869us-gaap:CustomerRelationshipsMember2024-01-012024-09-300001136869us-gaap:InProcessResearchAndDevelopmentMemberzbh:DistributorAndVideoInterventionnelleMedicaleScientifiqueAcquisitionMember2024-09-300001136869us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberzbh:ForwardStartingInterestRateSwapsMember2023-01-012023-09-300001136869us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2023-01-012023-09-300001136869us-gaap:CostOfSalesMember2023-07-012023-09-300001136869us-gaap:ConstructionInProgressMember2023-12-310001136869zbh:TwoThousandNineteenRestructuringPlanMemberus-gaap:OtherRestructuringMember2024-01-012024-09-300001136869zbh:NovemberTwoThousandTwentyThreeAcquisitionMember2023-11-150001136869zbh:TwoThousandTwentyFourFiveYearCreditAgreementMemberzbh:MultiCurrencyRevolvingFacilityMember2024-06-282024-06-280001136869zbh:EuroNotesMember2024-01-012024-09-300001136869us-gaap:NoncontrollingInterestMember2023-06-300001136869us-gaap:TreasuryStockCommonMember2023-09-300001136869zbh:TwoPointFourTwoFivePercentageNotesDueTwoThousandTwentySixMember2024-01-012024-09-300001136869us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001136869us-gaap:CommonStockMembersrt:MaximumMemberzbh:EmbodyIncMember2023-02-140001136869us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberzbh:ForwardStartingInterestRateSwapsMember2023-07-012023-09-300001136869us-gaap:NoncontrollingInterestMember2023-12-310001136869us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-07-012024-09-30iso4217:EURiso4217:USDxbrli:sharesxbrli:pureiso4217:JPYxbrli:shareszbh:OrthopedicApplicationsiso4217:CHFzbh:Segmentiso4217:USD

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED September 30, 2024

Commission File Number 001-16407

 

ZIMMER BIOMET HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

13-4151777

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

345 East Main Street, Warsaw, IN 46580

(Address of principal executive offices)

Telephone: (574) 373-3333

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 par value

ZBH

New York Stock Exchange

2.425% Notes due 2026

ZBH 26

New York Stock Exchange

1.164% Notes due 2027

ZBH 27

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☒

 

 

Accelerated filer

☐

 

 

 

 

 

Non-accelerated filer

☐

Smaller reporting company

☐

 

 

 

 

Emerging growth company

☐

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of October 25, 2024, 199,073,712 shares of the registrant’s $.01 par value common stock were outstanding.

 

 

 

ZIMMER BIOMET HOLDINGS, INC.

INDEX TO FORM 10-Q

September 30, 2024

 

 

 

 

Page

 

 

 

Part I - Financial Information

 

 

 

 

 

 

 

Item 1.

 

Financial Statements (unaudited)

 

3

 

 

Condensed Consolidated Statements of Earnings for the Three and Nine Months Ended September 30, 2024 and 2023

 

3

 

 

Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2024 and 2023

 

4

 

 

Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023

 

5

 

 

Condensed Consolidated Statements of Stockholders’ Equity for the Three and Nine Months Ended September 30, 2024 and 2023

 

6

 

 

Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023

 

7

 

 

Notes to Interim Condensed Consolidated Financial Statements

 

8

 

 

 

 

 

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

27

 

 

 

 

 

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

 

35

 

 

 

 

 

Item 4.

 

Controls and Procedures

 

35

 

 

 

Part II - Other Information

 

 

 

 

 

 

 

Item 1.

 

Legal Proceedings

 

37

 

 

 

 

 

Item 1A.

 

Risk Factors

 

37

 

 

 

 

 

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

 

37

 

 

 

 

 

Item 3.

 

Defaults Upon Senior Securities

 

37

 

 

 

 

 

Item 4.

 

Mine Safety Disclosures

 

38

 

 

 

 

 

Item 5.

 

Other Information

 

38

 

 

 

 

 

Item 6.

 

Exhibits

 

39

 

 

 

Signatures

 

40

 

2

 

Part I – Financial Information

Item 1. Financial Statements

ZIMMER BIOMET HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS

(in millions, except per share amounts, unaudited)

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Net Sales

 

$

1,824.2

 

 

$

1,753.6

 

 

$

5,655.4

 

 

$

5,454.1

 

Cost of products sold, excluding intangible asset amortization

 

 

538.6

 

 

 

518.6

 

 

 

1,604.5

 

 

 

1,545.0

 

Intangible asset amortization

 

 

148.2

 

 

 

145.0

 

 

 

434.3

 

 

 

416.6

 

Research and development

 

 

111.6

 

 

 

116.9

 

 

 

328.9

 

 

 

345.4

 

Selling, general and administrative

 

 

709.7

 

 

 

674.9

 

 

 

2,182.9

 

 

 

2,116.6

 

Restructuring and other cost reduction initiatives

 

 

32.2

 

 

 

24.3

 

 

 

198.1

 

 

 

90.6

 

Acquisition, integration, divestiture and related

 

 

4.4

 

 

 

7.3

 

 

 

9.9

 

 

 

16.4

 

Operating expenses

 

 

1,544.7

 

 

 

1,487.0

 

 

 

4,758.6

 

 

 

4,530.6

 

Operating Profit

 

 

279.5

 

 

 

266.6

 

 

 

896.7

 

 

 

923.5

 

Other income, net

 

 

5.1

 

 

 

3.8

 

 

 

7.0

 

 

 

10.3

 

Interest expense, net

 

 

(54.3

)

 

 

(51.1

)

 

 

(156.1

)

 

 

(150.9

)

Earnings before income taxes

 

 

230.3

 

 

 

219.2

 

 

 

747.6

 

 

 

782.8

 

(Benefit) provision for income taxes

 

 

(18.9

)

 

 

56.4

 

 

 

82.5

 

 

 

177.4

 

Net Earnings

 

 

249.2

 

 

 

162.8

 

 

 

665.1

 

 

 

605.4

 

Less: Net earnings attributable to noncontrolling interest

 

 

0.2

 

 

 

0.2

 

 

 

0.8

 

 

 

0.6

 

Net Earnings of Zimmer Biomet Holdings, Inc.

 

$

249.1

 

 

$

162.7

 

 

$

664.3

 

 

$

604.8

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings Per Common Share

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

1.23

 

 

$

0.78

 

 

$

3.25

 

 

$

2.89

 

Diluted

 

$

1.23

 

 

$

0.77

 

 

$

3.24

 

 

$

2.88

 

Weighted Average Common Shares Outstanding

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

202.3

 

 

 

208.9

 

 

 

204.4

 

 

 

209.0

 

Diluted

 

 

203.0

 

 

 

210.0

 

 

 

205.2

 

 

 

210.1

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

 

ZIMMER BIOMET HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in millions, unaudited)

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Net Earnings of Zimmer Biomet Holdings, Inc.

 

$

249.1

 

 

$

162.7

 

 

$

664.3

 

 

$

604.8

 

Other Comprehensive Income (Loss):

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency cumulative translation adjustments, net of tax

 

 

61.1

 

 

 

(22.7

)

 

 

21.2

 

 

 

(36.7

)

Unrealized cash flow hedge (losses) gains, net of tax

 

 

(49.9

)

 

 

33.8

 

 

 

22.8

 

 

 

89.7

 

Reclassification adjustments on hedges, net of tax

 

 

(17.1

)

 

 

(19.1

)

 

 

(52.9

)

 

 

(57.4

)

Adjustments to prior service cost and unrecognized actuarial assumptions, net of tax

 

 

(1.1

)

 

 

(0.7

)

 

 

(2.3

)

 

 

(2.8

)

Total Other Comprehensive Income (Loss)

 

 

(7.0

)

 

 

(8.7

)

 

 

(11.2

)

 

 

(7.2

)

Comprehensive Income Attributable to

 

 

 

 

 

 

 

 

 

 

 

 

Zimmer Biomet Holdings, Inc.

 

$

242.1

 

 

$

154.0

 

 

$

653.1

 

 

$

597.6

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

 

ZIMMER BIOMET HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions, except share amounts, unaudited)

 

 

September 30,

 

 

December 31,

 

 

 

2024

 

 

2023

 

ASSETS

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

569.0

 

 

$

415.8

 

Accounts receivable, less allowance for credit losses

 

 

1,481.5

 

 

 

1,442.4

 

Inventories

 

 

2,368.7

 

 

 

2,385.2

 

Prepaid expenses and other current assets

 

 

444.8

 

 

 

366.1

 

Total Current Assets

 

 

4,864.0

 

 

 

4,609.5

 

Property, plant and equipment, net

 

 

2,107.2

 

 

 

2,060.4

 

Goodwill

 

 

8,912.3

 

 

 

8,818.5

 

Intangible assets, net

 

 

4,665.3

 

 

 

4,856.4

 

Other assets

 

 

1,171.6

 

 

 

1,152.1

 

Total Assets

 

$

21,720.3

 

 

$

21,496.9

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

Accounts payable

 

$

322.4

 

 

$

410.6

 

Other current liabilities

 

 

1,536.0

 

 

 

1,546.9

 

Current portion of long-term debt

 

 

1,713.0

 

 

 

900.0

 

Total Current Liabilities

 

 

3,571.3

 

 

 

2,857.4

 

Other long-term liabilities

 

 

1,028.1

 

 

 

1,283.4

 

Long-term debt

 

 

4,737.7

 

 

 

4,867.9

 

Total Liabilities

 

 

9,337.1

 

 

 

9,008.7

 

Commitments and Contingencies (Note 15)

 

 

 

 

 

 

Stockholders' Equity:

 

 

 

 

 

 

Zimmer Biomet Holdings, Inc. Stockholders' Equity:

 

 

 

 

 

 

Common stock, $0.01 par value, one billion shares authorized, 317.4 million shares as of September 30, 2024 (316.2 million as of December 31, 2023) issued

 

 

3.2

 

 

 

3.2

 

Paid-in capital

 

 

10,017.5

 

 

 

9,846.1

 

Retained earnings

 

 

10,903.7

 

 

 

10,384.5

 

Accumulated other comprehensive loss

 

 

(202.2

)

 

 

(191.0

)

Treasury stock, 117.8 million shares as of September 30, 2024 (110.6 million as of December 31, 2023)

 

 

(8,347.5

)

 

 

(7,562.3

)

Total Zimmer Biomet Holdings, Inc. stockholders' equity

 

 

12,374.7

 

 

 

12,480.5

 

Noncontrolling interest

 

 

8.5

 

 

 

7.7

 

Total Stockholders' Equity

 

 

12,383.2

 

 

 

12,488.1

 

Total Liabilities and Stockholders' Equity

 

$

21,720.3

 

 

$

21,496.9

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

 

ZIMMER BIOMET HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in millions, except per share amounts, unaudited)

 

 

 

Zimmer Biomet Holdings, Inc. Stockholders

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

 

 

 

 

 

Total

 

 

 

Common Shares

 

 

Paid-in

 

 

Retained

 

 

Comprehensive

 

 

Treasury Shares

 

 

Noncontrolling

 

 

Stockholders'

 

 

 

Number

 

 

Amount

 

 

Capital

 

 

Earnings

 

 

(Loss) Income

 

 

Number

 

 

Amount

 

 

Interest

 

 

Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance July 1, 2024

 

 

317.2

 

 

$

3.2

 

 

$

9,974.9

 

 

$

10,702.5

 

 

$

(195.2

)

 

 

(112.3

)

 

$

(7,744.3

)

 

$

8.4

 

 

$

12,749.4

 

Net earnings

 

 

-

 

 

 

-

 

 

 

-

 

 

 

249.1

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

0.2

 

 

 

249.3

 

Other comprehensive loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(7.0

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(7.0

)

Cash dividends declared
($0.24 per share)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(47.9

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(47.9

)

Stock compensation plans

 

 

0.2

 

 

 

-

 

 

 

42.6

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

42.6

 

Share repurchases

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(5.5

)

 

 

(603.3

)

 

 

-

 

 

 

(603.3

)

Balance September 30, 2024

 

 

317.4

 

 

$

3.2

 

 

$

10,017.5

 

 

$

10,903.7

 

 

$

(202.2

)

 

 

(117.8

)

 

$

(8,347.5

)

 

$

8.5

 

 

$

12,383.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance July 1, 2023

 

 

315.8

 

 

$

3.2

 

 

$

9,766.0

 

 

$

9,902.3

 

 

$

(177.8

)

 

 

(107.0

)

 

$

(7,122.2

)

 

$

7.1

 

 

$

12,378.6

 

Net earnings

 

 

-

 

 

 

-

 

 

 

-

 

 

 

162.7

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

0.2

 

 

 

162.9

 

Other comprehensive loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(8.7

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(8.7

)

Cash dividends declared
($0.24 per share)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(50.1

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(50.1

)

Stock compensation plans

 

 

0.2

 

 

 

-

 

 

 

35.4

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

35.4

 

Balance September 30, 2023

 

 

316.0

 

 

$

3.2

 

 

$

9,801.4

 

 

$

10,014.9

 

 

$

(186.5

)

 

 

(107.0

)

 

$

(7,122.2

)

 

$

7.2

 

 

$

12,518.0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance January 1, 2024

 

 

316.2

 

 

$

3.2

 

 

$

9,846.1

 

 

$

10,384.5

 

 

$

(191.0

)

 

 

(110.6

)

 

$

(7,562.3

)

 

$

7.7

 

 

$

12,488.1

 

Net earnings

 

 

-

 

 

 

-

 

 

 

-

 

 

 

664.3

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

0.8

 

 

 

665.1

 

Other comprehensive loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(11.2

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(11.2

)

Cash dividends declared
($0.72 per share)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(146.5

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(146.5

)

Stock compensation plans

 

 

1.0

 

 

 

-

 

 

 

148.0

 

 

 

1.4

 

 

 

-

 

 

 

-

 

 

 

1.4

 

 

 

-

 

 

 

150.8

 

Embody, Inc. acquisition consideration

 

 

0.2

 

 

 

-

 

 

 

23.4

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

23.4

 

Share repurchases

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(7.2

)

 

 

(786.7

)

 

 

-

 

 

 

(786.7

)

Balance September 30, 2024

 

 

317.4

 

 

$

3.2

 

 

$

10,017.5

 

 

$

10,903.7

 

 

$

(202.2

)

 

 

(117.8

)

 

$

(8,347.5

)

 

$

8.5

 

 

 

12,383.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance January 1, 2023

 

 

313.8

 

 

$

3.1

 

 

$

9,504.4

 

 

$

9,559.3

 

 

$

(179.3

)

 

 

(104.8

)

 

$

(6,867.2

)

 

$

6.7

 

 

$

12,027.0

 

Net earnings

 

 

-

 

 

 

-

 

 

 

-

 

 

 

604.8

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

0.6

 

 

 

605.4

 

Other comprehensive loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(7.2

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(7.2

)

Cash dividends declared
($0.72 per share)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(150.6

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(150.6

)

Stock compensation plans

 

 

1.0

 

 

 

-

 

 

 

148.9

 

 

 

1.4

 

 

 

-

 

 

 

-

 

 

 

1.0

 

 

 

-

 

 

 

151.3

 

Embody, Inc. acquisition consideration

 

 

1.2

 

 

 

0.1

 

 

 

150.4

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

150.5

 

Share repurchases

 

 

-

 

 

 

-

 

 

 

(2.3

)

 

 

-

 

 

 

-

 

 

 

(2.2

)

 

 

(256.0

)

 

 

-

 

 

 

(258.3

)

Balance September 30, 2023

 

 

316.0

 

 

$

3.2

 

 

$

9,801.4

 

 

$

10,014.9

 

 

$

(186.5

)

 

 

(107.0

)

 

$

(7,122.2

)

 

$

7.2

 

 

$

12,518.0

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

 

ZIMMER BIOMET HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in millions, unaudited)

 

 

 

 

 

 

For the Nine Months Ended September 30,

 

 

 

2024

 

 

2023

 

Cash flows provided by (used in) operating activities:

 

 

 

 

 

 

Net earnings

 

$

665.1

 

 

$

605.4

 

Adjustments to reconcile net earnings to cash provided
   by operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

732.7

 

 

 

710.5

 

Share-based compensation

 

 

79.9

 

 

 

74.5

 

Changes in operating assets and liabilities, net of acquired assets and liabilities

 

 

 

 

 

 

Income taxes

 

 

(181.2

)

 

 

23.4

 

Receivables

 

 

(40.1

)

 

 

15.5

 

Inventories

 

 

(38.0

)

 

 

(212.2

)

Accounts payable and accrued liabilities

 

 

(204.7

)

 

 

(219.5

)

Other assets and liabilities

 

 

(20.5

)

 

 

(4.5

)

       Net cash provided by operating activities

 

 

993.1

 

 

 

993.2

 

Cash flows provided by (used in) investing activities:

 

 

 

 

 

 

Additions to instruments

 

 

(188.4

)

 

 

(232.8

)